Should We Be Cautious About Integra LifeSciences Holdings Corporation's (NASDAQ:IART) ROE Of 1.5%?
Integra LifeSciences Holdings (NASDAQ:IART) Stock Falls 9.0% in Past Week as Three-year Earnings and Shareholder Returns Continue Downward Trend
Wells Fargo Downgrades Integra Lifesciences(IART.US) to Hold Rating, Cuts Target Price to $25
Wells Fargo analyst Vik Chopra downgrades $Integra Lifesciences(IART.US)$ to a hold rating, and adjusts the target price from $45 to $25.According to TipRanks data, the analyst has a success rate of 1
Integra Lifesciences: Hold Rating Amidst Compliance Challenges and Revenue Impact With a Long-Term Recovery Outlook
Integra LifeSciences to Present at the 2024 Wells Fargo Healthcare Conference
BTIG Maintains Integra Lifesciences(IART.US) With Sell Rating, Maintains Target Price $20
BTIG analyst Ryan Zimmerman maintains $Integra Lifesciences(IART.US)$ with a sell rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 48.2%